
KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused tracks on…

In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an exceptional…

In Episode 89 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio’s strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company’s transatlantic…

In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino, Ph.D. and John Perkins, Ph.D present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. David Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across…

Initially developed to assess the frequency of circulating antigen-specific Antibody-Secreting Cells (ASC), ELISpot has become a vital tool for quantifying antigen-reactive T-cells by measuring secreted immune mediators such as cytokines or key molecules involved in cell-mediated cytotoxicity. Compared to other assays for monitoring cell-mediated immunity (CMI), such as…

In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…

As the field of biotherapeutics rapidly evolves, the development of advanced conjugated therapies such as Antibody-Drug Conjugates (ADCs), Antibody-RNA Conjugates (ARCs), siRNA/oligos, and antibody-peptide conjugates has gained significant momentum. These next-generation therapeutics offer promising efficacy and safety profiles for treating various conditions, including cancer, rare diseases, and in vaccine development.

What Are Neutralizing Antibody (NAb) Assays? Neutralizing antibodies (NAbs) are a subset of anti-drug antibodies (ADAs) that play an important role in evaluating the immunogenicity, safety, and efficacy of a drug product. While most drugs carry a low risk of eliciting NAbs and do not require a validated NAb…

Last month, Elodie, Magali, and I found ourselves in Lisbon—not for a spring getaway (though the weather was a delightful preview of the season) and certainly not for ultra-trail training (although the city’s hills did give our calves a solid workout!). Instead, we were there for EIP, an event…

During episode 86 of KCAS Bio’s “The Weekly Bioanalysis” podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard…

Immunogenicity, why do we keep talking about it? Immunogenicity can, in the simplest of terms, be described as a subject’s ability to generate antibodies specific to the dosed protein therapeutic. While stating it this way understates the complexity of the immune system and the methods needed to detect and characterize…

KCAS Bio is excited to announce our participation in several premier conferences throughout the United States this fall. These events bring together experts, innovators, and leaders in pharmaceuticals, biotechnology, and clinical research to exchange insights, explore the latest technologies, and drive the future of scientific discovery. As a trusted provider…